Amineptine

Recent MI, arrhythmias, severe liver disease, manic phase. Porphyria. Lactation.

CV disease, history of epilepsy, hepatic impairment, hyperthyroidism, pheochromocytoma, history of mania, psychoses, close-angle glaucoma, history of urinary retention, concurrent electroconvulsive therapy, DM. Avoid abrupt withdrawal. May impair ability to drive and operate machines. Pregnancy. Elderly and children.

Marked antimuscarinic and CV effects. Dry mouth, sedation, blurred vision, constipation, difficulty in micturition, nausea, sweating, tremor, hypersensitivity reactions, behavioral disturbances, sexual dysfunction, blood sugar changes, increased appetite or wt gain. Testicular enlargement, gynecomastia, galactorrhoea. Convulsion, movement disorders, dyskinesias. Fever and blood disorders.

Plasma conc and effects may be enhanced by cimetidine, diltiazem, disulfiram, methylphenidate, ritonavir and verapamil. Side-effects may be increased by adrenaline, amiodarone, general anaesthetics, SSRIs, antihistamines, antimuscarinics, antipsychotics, anxiolytics and hypnotics, clozapine, disopyramide, diuretics, flecainide, MAOIs, moclobemide, moxifloxacin, nefopam, nicorandil, noradrenaline, pimozide, procainamide, propafenone, quinidine, selegiline, sibutramine, sotalol, terfenadine, thioridazine and tramadol. Effects of adrenergic neuron blocker, clonidine, barbiturates, nitrates, and primidone are reduced while effects of baclofen, opioid analgesics and thyroid hormones are enhanced. Carbamazepine and rifampicin may increase metabolism while its effects may be antagonised by oestrogens.
Potentially Fatal: Concomitant use with brimonidine, entacapone, artemether with lumefantrine, or sibutramine should be avoided.

Abnormal LFT.

Description: Amineptine is a TCA. It selectively inhibits the reuptake of dopamine and to a lesser extent norepinephrine, thus exerting a powerful and fast-acting antidepressant effect.

Antidepressants